Literature DB >> 7861501

Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study.

T C Theoharides1, G R Sant, M el-Mansoury, R Letourneau, A A Ucci, E M Meares.   

Abstract

Interstitial cystitis, a sterile bladder condition, is characterized by urinary frequency, urgency, burning and suprapubic pain. Increasing evidence indicates that interstitial cystitis is a heterogeneous syndrome that reflects an immune response to a variety of triggers. More than 50% of the patients have allergies, 30% have the irritable bowel syndrome and almost 20% suffer from migraine headaches. Increased numbers of mast cells have been reported in interstitial cystitis. Mast cell activation, which is critical if these cells were to be implicated in this syndrome, has been investigated by electron microscopy, which definitively shows mast cell secretion. Recently, methylhistamine, the major metabolite of histamine, and the specific mast cell marker, tryptase, were shown to be significantly elevated in urine of interstitial cystitis patients. Bladder biopsies from 53 patients were analyzed blindly for the number and degree of activation of mast cells using 4 different stains for light microscopy, as well as electron microscopy. Controls included 16 patients with incontinence and chronic bacterial cystitis. Mast cells in controls were less than 10/mm.2 and were all nearly intact. Surprisingly, mast cells from 11 cancer patients averaged 50/mm.2 but almost all were intact. In contrast, mast cells from 26 interstitial cystitis patients averaged 40/mm.2 and more than 90% were activated to various degrees. Therefore, bladder mast cell activation is a characteristic pathological finding in at least a subset of patients with interstitial cystitis.

Entities:  

Mesh:

Year:  1995        PMID: 7861501     DOI: 10.1097/00005392-199503000-00021

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  39 in total

1.  Tumor necrosis factor-α induces expression and release of interleukin-6 by human urothelial cells.

Authors:  Zun-Yi Wang; Dale E Bjorling
Journal:  Inflamm Res       Date:  2010-12-30       Impact factor: 4.575

2.  Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity.

Authors:  Dan Levy; Vanessa Kainz; Rami Burstein; Andrew M Strassman
Journal:  Brain Behav Immun       Date:  2011-10-12       Impact factor: 7.217

Review 3.  Interstitial cystitis.

Authors:  D R Erickson; M F Davies
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1998

Review 4.  Role of interleukin-18 in the pathophysiology of allergic diseases.

Authors:  Nathan L Sanders; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2016-07-15       Impact factor: 7.638

Review 5.  Models of inflammation of the lower urinary tract.

Authors:  Dale E Bjorling; Zun-Yi Wang; Wade Bushman
Journal:  Neurourol Urodyn       Date:  2011-06       Impact factor: 2.696

6.  New direct evidence that histamine augments bladder sensory outflow during filling is nothing to sneeze at.

Authors:  B Malique Jones; Nathan R Tykocki
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-06

7.  Voluntary wheel running attenuates urinary bladder hypersensitivity and dysfunction following neonatal maternal separation in female mice.

Authors:  Angela N Pierce; Olivia C Eller-Smith; Julie A Christianson
Journal:  Neurourol Urodyn       Date:  2018-02-21       Impact factor: 2.696

Review 8.  Painful bladder syndrome: an update and review of current management strategies.

Authors:  Anthony J Dyer; Christian O Twiss
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

9.  Treatment approaches for interstitial cystitis: multimodality therapy.

Authors:  Robert J Evans
Journal:  Rev Urol       Date:  2002

Review 10.  Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives.

Authors:  Yoshiyuki Akiyama; Yi Luo; Philip M Hanno; Daichi Maeda; Yukio Homma
Journal:  Int J Urol       Date:  2020-04-04       Impact factor: 3.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.